Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Afamitresgene autoleucel by Adaptimmune Therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....
Afamitresgene autoleucel by Adaptimmune Therapeutics for Neuroblastoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Osteosarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase...
Afamitresgene autoleucel by Adaptimmune Therapeutics for Synovial Sarcoma: Likelihood of Approval
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Pre-Registration for Synovial Sarcoma. According to GlobalData, Pre-Registration...
Risk adjusted net present value: What is the current valuation of Adaptimmune Therapeutics's Afamitresgene autoleucel?
Afamitresgene autoleucel is a gene-modified cell therapy commercialized by Adaptimmune Therapeutics, with a leading Pre-Registration program in Synovial Sarcoma. According...
Risk adjusted net present value: What is the current valuation of Adaptimmune Therapeutics's Afamitresgene autoleucel?
Afamitresgene autoleucel is a gene-modified cell therapy commercialized by Adaptimmune Therapeutics, with a leading Pre-Registration program in Synovial Sarcoma. According...